Get the Stockscreener App
57.48
2.57%
1.44
Protagonist Therapeutics Inc stock is traded at $57.48, with a volume of 470.08K.
It is up +2.57% in the last 24 hours and up +4.53% over the past month.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
See More
Previous Close:
$56.04
Open:
$56.52
24h Volume:
470.08K
Relative Volume:
0.61
Market Cap:
$3.58B
Revenue:
$45.48M
Net Income/Loss:
$169.95M
P/E Ratio:
21.94
EPS:
2.62
Net Cash Flow:
$230.85M
1W Performance:
+2.51%
1M Performance:
+4.53%
6M Performance:
+48.34%
1Y Performance:
+38.71%
1-Day Range:
$56.09
$57.72
1-Week Range:
$55.26
$57.99
52-Week Range:
$33.31
$60.60
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Name
Protagonist Therapeutics Inc
Sector
Industry
Phone
(510) 474-0170
Address
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
57.48 | 3.50B | 45.48M | 169.95M | 230.85M | 2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Citigroup | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-06-24 | Initiated | Goldman | Neutral |
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Sep-24-24 | Initiated | TD Cowen | Buy |
| Sep-09-24 | Initiated | Truist | Buy |
| Oct-30-23 | Initiated | CapitalOne | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Aug-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Oct-12-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-11-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Sep-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-24-21 | Initiated | JMP Securities | Mkt Outperform |
| May-24-21 | Initiated | Northland Capital | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Dec-16-20 | Initiated | Piper Sandler | Overweight |
| Sep-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Initiated | Jefferies | Buy |
| May-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| May-09-19 | Upgrade | Stifel | Hold → Buy |
| Dec-06-18 | Initiated | Nomura | Buy |
| Jan-29-18 | Initiated | Stifel | Buy |
| Jul-21-17 | Initiated | BTIG Research | Buy |
View All
Protagonist Therapeutics Inc Stock (PTGX) Latest News
Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Newport Daily News
Protagonist Therapeutics Inc. Stock Lags Behind Sector Benchmarks2025 Macro Impact & High Conviction Buy Zone Picks - newsyoung.net
STATE STREET CORP's Strategic Acquisition in Protagonist Therapeutics Inc - GuruFocus
Protagonist (PTGX) Q2 Revenue Falls 26% - AOL.com
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates - 富途牛牛
Protagonist Therapeutics Inc. Approaches Psychological Resistance LevelQuarterly Profit Report & Weekly Hot Stock Watchlists - thegnnews.com
Protagonist Therapeutics’ SWOT analysis: biotech firm’s stock poised for growth - Investing.com Canada
Exploring High Growth Tech Stocks In The US Market - simplywall.st
Does Protagonist Therapeutics’ (PTGX) Widening Loss and Shelf Registration Signal a Strategic Pivot? - Yahoo Finance
Protagonist Therapeutics shares rise 3.78% intraday amid global geopolitical tensions. - AInvest
Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Nektar Therapeutics (NKTR) - The Globe and Mail
Citi Analyst Maintains Buy Rating on Protagonist Therapeutics with $72.00 Price Target - AInvest
Protagonist Therapeutics: Promising Pipeline and Strategic Advancements Drive Buy Rating - TipRanks
Protagonist Therapeutics Completes Promising Phase 2 Study on PTG-300 for Polycythemia Vera - TipRanks
Protagonist Therapeutics’ Rusfertide Study: A Promising Update for Polycythemia Vera Treatment - TipRanks
Protagonist Therapeutics: Promising Future with Strong Pipeline and Financial Stability - TipRanks
Protagonist Therapeutics price target raised to $69 from $67 at Citizens JMP - TipRanks
Protagonist Therapeutics stock price target raised to $69 by JMP - Investing.com Canada
Protagonist Therapeutics Reports Q2 2025 Results and Pipeline Progress - TipRanks
Protagonist (PTGX) Q2 Revenue Falls 26% - The Motley Fool
Decoding Protagonist Therapeutics Inc (PTGX): A Strategic SWOT I - GuruFocus
Protagonist Therapeutics: Q2 Earnings Snapshot - Connecticut Post
Protagonist Therapeutics: Promising Developments in Rusfertide and Icotrokinra Drive Buy Rating - TipRanks
Protagonist Therapeutics earnings beat by $0.03, revenue fell short of estimates - Investing.com Canada
Why Protagonist Therapeutics Shares Are Dropping - TipRanks
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Protagonist Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Protagonist Therapeutics Q2 net loss beats expectations - MarketScreener
Protagonist Therapeutics’ Rusfertide Study: Long-term Safety in Focus - TipRanks
Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity - MSN
Does Protagonist Therapeutics Inc. stock pay reliable dividendsHigh Growth Low Risk Stock Selection Gets Analyst Nod - beatles.ru
Why is Protagonist Therapeutics Inc. stock attracting strong analyst attentionStay ahead with daily expert stock picks - Jammu Links News
What drives Protagonist Therapeutics Inc. stock priceHigh-octane financial growth - Jammu Links News
Does Protagonist Therapeutics Inc. stock perform well during market downturnsFree Stock Index Interpretation - Jammu Links News
What is Protagonist Therapeutics Inc. company’s growth strategyRapid return acceleration - Jammu Links News
Is it the right time to buy Protagonist Therapeutics Inc. stockAchieve rapid wealth accumulation with smart picks - Jammu Links News
What is the dividend policy of Protagonist Therapeutics Inc. stockUnlock exclusive stock market forecasts - Jammu Links News
Is Protagonist Therapeutics Inc. a growth stock or a value stockTremendous return on equity - Jammu Links News
What are the technical indicators suggesting about Protagonist Therapeutics Inc.Build wealth steadily with proven investment strategies - Jammu Links News
How does Protagonist Therapeutics Inc. compare to its industry peersHigh-octane investment gains - Jammu Links News
What catalysts could drive Protagonist Therapeutics Inc. stock higher in 2025Superior return velocity - Jammu Links News
How strong is Protagonist Therapeutics Inc. company’s balance sheetInvest confidently with professional market insights - Jammu Links News
Protagonist Therapeutics Inc. Stock Analysis and ForecastTriple-digit growth rates - Jammu Links News
Protagonist Therapeutics Inc Stock (PTGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Protagonist Therapeutics Inc Stock (PTGX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| PATEL DINESH V PH D | President and CEO |
Jul 22 '25 |
Sale |
55.05 |
22,065 |
1,214,678 |
548,538 |
| PATEL DINESH V PH D | President and CEO |
Jul 23 '25 |
Sale |
54.79 |
17,520 |
959,921 |
531,018 |
| PATEL DINESH V PH D | President and CEO |
Jul 21 '25 |
Sale |
54.86 |
12,859 |
705,445 |
570,603 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):